The aim of this study was to evaluate the influence of verapamil SR 240 mg (V) and the combination amiloride 5 mg + hydrochlorothiazide 50 mg (AH) on diastolic dysfunction of hypertensive patients without left ventricular hypertrophy (LVH). Twenty-six hypertensive patients with diastolic dysfunction, normal systolic function and without LVH were included into a 2-week washout period and then randomised to a 6-month V or AH treatment. One blinded-to-treatment echocardiographist at
Introduction
A delayed complication of hypertension is the development of left ventricular hypertrophy (LVH) with ventricular dysfunction. It is well recognised that diastolic dysfunction develops before LVH. The diastole is defined as the period of the cardiac cycle separating two consecutive contraction intervals. From a clinical point of view, it is admitted to include the relaxation and rapid filling phases. Diastolic dysfunction may be defined as the situation in which the relaxation and distensibility alterations modify the ventricular filling physiologic conditions. This dysfunction is asymptomatic in the majority of cases, being clinically recognised, at an advanced stage, by a decrease in the exertion capability with symptoms of pulmonary congestion. 1 In 1985, Inouye et al 2 demonstrated a negative correlation between blood pressure (BP) level and the peak-filling rate, independently of the presence and degree of LVH. Later, Phillips et al 3 found abnormal left ventricular filling rates only in patients with systolic BP (SBP) higher than 130 mm Hg, irrespective of left ventricular mass, but not in those patients with SBP lower than 130 mm Hg. These results in humans point towards the same conclusions obtained from preclinical studies, showing that an increase in afterload at the early filling phase has a deleterious effect on ventricular relaxation. baseline and at weeks 4, 12 and 24 assessed Dopplerechocardiography. Both V and AH, satisfactorily controlled blood pressure, but only V improved diastolic function shown by a tendency to reduce peak A and to increase peak E/A ratio, and by a significant reduction in deceleration time. After 24 weeks, V significantly reduced wall thickness in comparison with AH. These results need to be confirmed in a larger scale study.
Diastole is basically influenced by three factors:
The relaxation of the heart muscle, distensibility of the ventricular chamber, and the cycle frequency. Different drugs have been used to correct diastolic alterations: bradycardiac agents, which increase the filling time; lusotropic, to improve muscle relaxation; and antiremodelling substances, which improve distension of the chamber. Although treatment of asymptomatic diastolic dysfunction has not yet been proven to be necessary, one may suppose that returning to physiologic conditions of heart functional activity could be of benefit. Concerning antihypertensive drugs, there are a few reports on improvement of diastolic dysfunction in hypertensive patients without LVH treated with ACE inhibitors. 6, 7 Calcium antagonists and diuretics are also useful in controlling high BP (HBP); non-dihydropyridinic calcium antagonists, especially verapamil, exhibit a good profile on these patients: bradycardiac action, increasing the filling rate, and lusotropic, improving the ventricular relaxation through a complex mechanism of decreased intracellular calcium overload, reduction in functional ischaemia and steady relaxing conditions. 8, 9 Diuretics, besides decreasing congestive symptoms, if present, improve load conditions in both ventricles, indirectly reduce pericardic constriction and ventricular cross-talk conditions, thus improving ventricular filling. 10 Moreover, possible drug effects on diastolic dysfunction might be independent of those on left ventricular mass, a hypothesis to be tested in patients with diastolic dysfunction without LVH.
The aim of this study is to compare the effects of a 6-month treatment with verapamil (V) or amiloride plus hydrochlorothiazide combination (AH) on left ventricular diastolic dysfunction in hypertensive patients without LVH.
Materials and methods
This was a controlled, parallel, randomised study in hypertensive patients without LVH, conducted in an open-label fashion and assessed by a blinded-totreatment echocardiographist. Twenty-seven patients from both sexes and aged 18 years or more, referred for consultation in our hospital were recruited; they had not been previously treated or had discontinued their usual medication at least 6 months prior to entry into the study; all of them with a left ventricular mass index р130 g/m 2 in men and р100 g/m 2 in women. All patients gave their informed consent before enrolment in the study. One withdrew before starting on active medication. Subjects were excluded if presenting any of the following conditions: body mass index у30 kg/m 2 -due to the usual presence of LVH and to the 'poor acoustic window', secondary hypertension, sick sinus syndrome, 2nd and 3rd AV block, ischaemic heart disease, severe renal or hepatic insufficiency, concomitant treatment with antihypertensive drugs and known or suspected allergy to V or AH.
After a 2-week wash-out period to antihypertensive drugs, the 26 patients included were randomised to V slow release, 240 mg/day daily (11 patients) or amiloride 5 mg + hydrochlorothiazide 50 mg (AH) daily (15 patients 
Blood pressure
At baseline, three BP readings were performed at 1-week intervals, always taken in a sitting position, using a sphygmomanometer of Hg and following the Joint National Committee Recommendations.
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Patients with SBP у140 mm Hg and/or DBP у90 and Ͻ115 mm Hg were selected.
Doppler-echocardiography
The instrument used was a Toshiba Sonolayer SSH-160A, with a phase array probe of 3.75 MHz and 2.5 MHz for continuous and pulsed-Doppler imaging. M-mode echocardiograms guided by two-dimensional imaging were obtained from the left parasternal window, selecting a perpendicular beam to the left ventricle large axis, next to the mitral valves without intercepting them. The left ventricular internal diameters, posterior wall thickness and interventricular septum were determined according to the Penn Convention, and left ventricular mass per the Devereux formula. 12 The ventricular volumes and indices of systolic function were calculated by the Teicholz method. Left ventricular wall stress (an estimate of the force resisting systolic shortening of the myofibrils) was also calculated according to the usual formula to estimate the overload produced by arterial hypertension. 13 Diastolic function was studied through the analysis of transmitral flow by pulsed-Doppler. The curve of pulsed-Doppler was obtained from the apical four-chamber view with the sample volume placed where the filling speed was maximum-usually with the mean point at the level of the tip of the mitral valve in diastole. The ultrasonic beam was oriented coaxially to the flow of blood; the peak E and peak A, the peak E/A ratio and deceleration time (DT) were averaged on 5 consecutive cardiac cycles. We considered the presence of diastolic dysfunction when the value of any of these parameters exceeded in two standard deviations the normal means in our environment: peak E Ͼ0.55 m/sec, peak A Ͼ0.82 m/sec, E/A ratio Ͻ1 and DT Ͼ220 msec.
14 The intraobserver variability, previously known at our laboratory, presented a Kappa concordance index = 0.89.
Laboratory
Routine blood analysis was performed, complete blood count and biochemistry, at baseline and at 24 weeks of treatment, for safety reasons.
Statistical analysis
Data are expressed as mean ± standard deviation. Within group longitudinal analysis was performed by the ANOVA test for repeated measurements. For between group transversal comparison, Student's ttest was performed at baseline and after 4, 12 and 24 treatment weeks. In case of significant differences at baseline, covariance analysis, using baseline values as covariates, was performed, deducting the influence of baseline values. P values of р0.05 were regarded as significant.
Results

Population
Twenty-six patients, 11 men and 15 women, with mean age of 55.2 ± 7.2 years (27-72 years), were included in the study. Eleven patients were randomised to verapamil (V) and 15 patients were randomised to amiloride + hydrochlorothiazide (AH). Significant differences between groups were not found at baseline in age, sex distribution, body surface, SBP, DBP, heart rate and laboratory tests (not shown). There were no differences in the echocardiographic parameters. All patients had a normal systolic function, with ejection fraction greater than 55%, and a diastolic dysfunction as defined above. There were significant differences at baseline in the peak E ratio (V: 0.76 ± 0.16; AH: 0.65 ± 0.12; P = 0.046) ( Table 1) . 
Blood pressure
SBP and DBP significantly decreased from the fourth week of treatment by both, V and AH (Figure 1 ). Differences in SBP and DBP between drugs were not found at any observation time. V gradually decreased heart rate throughout the study (Figure 1) . The percentage of patients with DBP р90 mm Hg at different observation times were: week 4: V, 72.7%; AH, 66.7%; week 12: V, 81.8%; AH, 78.6%; week 24: V, 100%; AH, 83.3%.
Echocardiography
Mean echocardiographic values during the study are presented in Table 2 for both treatments. Ventricular volumes and diameters were not modified by V. The Table 2 Mean echocardiographic values during the study 49.7 ± 9 4 9 ± 9 51.8 ± 5 53.2 ± 5.1 P Ͻ 0.1 DPWT (mm) 9.4 ± 0.8 9.4 ± 0.8 9.4 ± 0.5 9.4 ± 0.3 NS ST (mm) 9.4 ± 0.6 9.4 ± 0.6 9.5 ± 0.6 9.5 ± 0. ejection fraction and shortening fraction showed a tendency to reduction (P Ͻ 0.1 in both cases), but remained within non-pathological values. The systolic left ventricular wall stress was significantly decreased by both V and AH. The AH group showed a trend of left ventricular telediastolic diameter (LVDD) increase (P Ͻ 0.1), without significant variations in the remaining parameters, except for ventricular stress, which was significantly reduced from week 4. There was no change in wall thickness. At the end of the study (week 24), significant differences between groups in diastolic posterior wall thickness (DPWT) were found (P Ͻ 0.01), with a lower level of thickness in the V group.
Doppler
Mean Doppler-echocardiography values through the study with V and AH are shown in Figure 2 .
An improvement in diastolic function was detected only in those patients treated with V. It was characterised by: a tendency to decrease the peak A and to increase the peak E/A ratio (P Ͻ 0.1 in both cases), as well as a significant decrease in the deceleration time (P Ͻ 0.05). No changes in Doppler parameters were detected in patients treated with AH.
Along the study, significant differences between groups were found in peak A, with lower mean values in the V group than in the AH group (weeks 12 and 24: P Ͻ 0.1 and P Ͻ 0.5, respectively), and deceleration time, lower in the V group than in the AH group (weeks 4, 12 and 24: P Ͻ 0.05, P Ͻ 0.05 and P Ͻ 0.01, respectively). Since differences between groups at baseline were found in peak E and the peak E/A ratio, covariance analysis using baseline values as covariant were performed in both cases (Table 3) . Differences between adjusted means were detected in peak E (weeks 12 and 24: P Ͻ 0.1 and P Ͻ 0.5, respectively) and the peak E/A ratio (weeks 4, 12 and 24: P Ͻ 0.05, P Ͻ 0.05 and P Ͻ 0.001, respectively).
Safety analysis
No side effects were spontaneously reported during the study. Small but significant changes in blood counts and biochemistry were found. A significant reduction in white cell count was detected in the V group (baseline: 6.8 ± 1.0 [× 10 ]; P Ͻ 0.05); increase of serum creatinine (baseline: 0.92 ± 0.18 mg/dL; week 24: 1.02 ± 0.24 mg/dL; P Ͻ 0.05); increase of uric acid (baseline: 5.4 ± 1.0 mg/dL; week 24: 5.9 ± 1.2 mg/dL; P Ͻ 0.001); increase of serum glucose (baseline: 96.4 ± 11.0 mg/dL; week 24: 101.8 ± 11.6 mg/dL; P Ͻ 0.01); increase of serum cholesterol (baseline: 221 ± 38 mg/dL; week 24: 226 ± 35 mg/dL; P Ͻ 0.05); and increase in blood urea nitrogen (baseline: 36 ± 7 mg/dL; week 24: 41 ± 8 mg/dL; P Ͻ 0.001).
Significant differences between groups at week 24 were found in the following biochemical para- Intergroup analysis: mean comparison for independent groups and ANCOVA (peak E and the peak E/A ratio, Table 2 ). meters: creatinine (P Ͻ 0.01), uric acid (P Ͻ 0.05), glucose (P Ͻ 0.05), cholesterol (P Ͻ 0.05) and urea (P Ͻ 0.01). In all cases, changes in the biochemical parameters were greater in the AH than in the V group.
Discussion
There are two types of mechanisms influencing the establishment of diastolic dysfunction in mild to moderate hypertension, dynamic and structural. 15 Fouad et al 16 considers as dynamic factors those conditions which, due to their functional character, may be modified and controlled in a short period of time. Among these factors, afterload, abnormal kinetics of calcium-associated with the development of LVH-general or regional myocardial ischaemia and sympathetic activity. The structural mechanisms are organic and linked to the development of LVH. The most important being muscle remodelling-resulting in concentric hypertrophyand the increase of collagen-resulting in perivascular and interstitial fibrosis-both conditions are secondary to hormonal stimulus like angiotensin II and aldosterone. 17 The transmitral diastolic flow has proven to be useful to study ventricular filling, since it is easily reproduced, non-invasive and inexpensive. Nevertheless, it is an indirect method to evaluate the diastole. Although variations in ventricular filling rate do not exactly reflect the diastolic function condition, they well reflect compliance of the ventricular chamber. Wall stiffness depends on multiple factors: cavity volume, wall thickness, myocardial stiffness and pericardium influences, right ventricle and myocardial vascularization; it is therefore not possible to measure the influence of each of these factors. The E-wave rate reflects instantaneous changes between left atrium pressure and ventricular relaxation, while the deceleration time is related to chamber stiffness and A-wave with atrial function, its pre-and postload, and its contractile capacity. 18 All these variables are divided in two types: Structural, basically due to physical characteristics of the chamber, and functional, derived from the pressure-volume conditions. The present study was performed on hypertensive patients with-out LVH. Thus, diastolic dysfunction was determined mainly by dynamic factors, being that the role of structural factors is insignificant.
Concerning BP control, our results coincide with other reports [19] [20] [21] [22] [23] [24] [25] [26] and both treatments efficiently controlled BP both at short-and long-term. Blood pressure reduction produced a decrease in afterload, which in turn could explain the reduction in ventricular stress seen with both therapies.
Although our patients did not show LVH, distensibility was affected, which was deduced by alterations in the deceleration time and A-wave. Nevertheless, these patients presented a conserved relaxation since their E-wave was normal. Diastolic dysfunction was only improved in the V group. The improvement was evidenced in the rapid filling phase of the left ventricle, as shown by the shortening in the deceleration period of the E-wave. The underlying mechanism seems to be independent of the afterload reduction, since the improvement was not detected with diuretic medication in spite of the registered afterload decrease. Some other mechanisms of action known to V, like the influence on calcium kinetics, sympathetic modulation and improvement of possible coexistent endothelial dysfunction or coronary microvascular disease [27] [28] [29] [30] (probably responsible for the difficulty in ventricular filling 29, 30 ), could be related to the improvement of diastolic dysfunction. The E/A ratio, as expression of the overall changes in diastolic function, was normalised in those patients treated with V, while it was not modified in the AH group. It is well recognised that diastolic function is decreased in the elderly. Only one patient in our study was above 65 years of age; thus, the possible drug effects do not seem to have been modified by age.
Although patients included in the study did not show increased ventricular mass at baseline, a reduction of left ventricular posterior wall thickness was documented in patients treated with V, previously reported by other authors. 20, 29 High levels of plasmatic catecholamines play an important role in LVH development. 30 Verapamil does not increase catecholamine synthesis, but reduces the postganglionar synthesis of noradrenaline 31 with a beneficial effect on LVH development. Moreover, some other mechanisms may be involved in the reduction of LVH by V, as its effect on the renin-angiotensinaldosterone axis by interfering with the calcium metabolism in the distal convoluted tubule [32] [33] [34] or decreasing the collagen content was seen in hypertensive rats. 35 Systolic function was not substantially modified by either treatment. An ejection fraction decrease in patients with depressed systolic function treated with V has been previously described. In our results, V showed a tendency to reduce the ejection fraction with non-pathological values, suggesting that the negative inotropic effect was compensated by the vasodilating effect of V.
Verapamil did not induce relevant changes in blood biochemistry. On the contrary, and according to other reports, 36, 37 AH significantly increased serum levels of glucose, uric acid, creatinine, cholesterol and urea.
The scope of our results is constrained by two limitations: first, at the time the protocol was designed there was scarce information on the influence of V and AH on diastolic function of hypertensive patients without LVH, making it difficult to predetermine the study sample size. Thus, these results must be seen as a preliminary report, pending of a well tailored confirmative study. Secondly, the study was conducted in an open label fashion, this being a possible biasing factor. Nevertheless, echocardiographic evaluation, the main topic of the study, was assessed by one blinded-to-treatment echocardiographist, which usually represents a methodological guarantee sufficient to evaluate ventricular function. 38 The beneficial effects of verapamil on diastolic function are well known, but to our knowledge, this is the first description of its improvement with verapamil in hypertensive patients without LVH.
In conclusion, V and AH are useful to control high BP, but only V improves the ventricular diastolic function. This calcium antagonist reduces wall thickness, even in patients with ventricular mass within non-pathological limits.
